Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E15.32 EPS (ttm)4.16 Insider Own0.40% Shs Outstand1.30B Perf Week-1.89%
Market Cap82.83B Forward P/E9.19 EPS next Y6.94 Insider Trans-3.20% Shs Float1.27B Perf Month-2.97%
Income5.46B PEG- EPS next Q1.62 Inst Own82.50% Short Float0.81% Perf Quarter-0.79%
Sales22.13B P/S3.74 EPS this Y-45.60% Inst Trans0.17% Short Ratio1.35 Perf Half Y-14.75%
Book/sh16.63 P/B3.84 EPS next Y4.63% ROA8.40% Target Price80.43 Perf Year-15.59%
Cash/sh23.17 P/C2.75 EPS next 5Y-3.60% ROE25.20% 52W Range60.32 - 79.61 Perf YTD1.98%
Dividend2.52 P/FCF18.39 EPS past 5Y18.10% ROI12.30% 52W High-19.87% Beta1.18
Dividend %3.95% Quick Ratio3.30 Sales past 5Y14.60% Gross Margin78.10% 52W Low5.75% ATR1.24
Employees11000 Current Ratio3.40 Sales Q/Q-2.60% Oper. Margin37.60% RSI (14)42.41 Volatility2.06% 1.87%
OptionableYes Debt/Eq1.28 EPS Q/Q-98.90% Profit Margin24.70% Rel Volume1.00 Prev Close63.77
ShortableYes LT Debt/Eq1.15 EarningsMay 06 AMC Payout54.30% Avg Volume7.65M Price63.79
Recom2.20 SMA20-1.47% SMA50-4.29% SMA200-9.98% Volume7,686,772 Change0.03%
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Mar-25-19 05:50PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-24-19 09:00AM  Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25% Motley Fool
Mar-22-19 05:43PM  Conatus (CNAT) Declines on Failure of NASH Fibrosis Study Zacks
10:20AM  Biogen Stock Fell Too Far on Unfortunate News InvestorPlace
Mar-21-19 07:56AM  Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons InvestorPlace
Mar-19-19 05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-18-19 04:09PM  New shareholder challenge to Gilead: What are you doing with billions in tax savings? American City Business Journals
12:26PM  Gilead Sciences Increased Some Drug Prices. Why Thats Good News and Bad News for the Stock. Barrons.com
10:45AM  YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day Zacks
09:42AM  With parting gifts, Gilead CEO's compensation soared American City Business Journals
06:23AM  Bear of the Day: Gilead Sciences (GILD) Zacks
Mar-17-19 07:31AM  Better Buy: Amgen vs. Gilead Sciences Motley Fool
Mar-14-19 11:13AM  Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up Zacks
Mar-13-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-09-19 06:00AM  3 Top Biotech Stocks to Buy in March Motley Fool
Mar-08-19 06:15PM  Stocks That Fell to 3-Year Lows in the Week of March 8 GuruFocus.com
03:46PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
10:20AM  Dont Abandon Gilead Stock After Weak Q4 Results InvestorPlace
Mar-07-19 05:30PM  Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies Business Wire
01:53PM  10 Top Pot Stocks 2019 Has to Offer InvestorPlace
01:50PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
01:45AM  [$$] Monthly jab for HIV treatment passes late-stage trials Financial Times
Mar-06-19 05:30PM  Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women Business Wire
05:30PM  Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance Business Wire
02:10PM  Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection Business Wire
11:23AM  Can Gilead Sciences Return to Winning Ways? GuruFocus.com
09:50AM  As new Gilead CEO enters, cancer chief exits American City Business Journals
09:30AM  Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report? Zacks
08:16AM  3 Big Pharmas Trying to Pop the Rebate Bubble Motley Fool
Mar-05-19 06:57PM  U.S. FDA chief tough on e-cigs steps down in surprise resignation Reuters
04:30PM  Gilead Announces Senior Management Change Business Wire
04:05PM  Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12 Business Wire
Mar-04-19 08:20AM  Triangle life sciences company files paperwork to raise $100M American City Business Journals
07:46AM  Why Sangamo Therapeutics Lost 22.9% of Its Value in February Motley Fool
Mar-01-19 11:49AM  Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus Zacks
09:26AM  Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended Zacks
06:22AM  Does Gilead Sciences, Inc. (NASDAQ:GILD) Have A Good P/E Ratio? Simply Wall St.
Feb-28-19 07:45AM  Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-27-19 01:25PM  Is Viking Therapeutics a Buy? Motley Fool
07:48AM  Gilead Sciences Inc (GILD) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-26-19 04:30PM  Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV Business Wire
06:48AM  Gilead Sciences Inc (GILD) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-25-19 03:25PM  5 Clinical-Stage Biotech Stocks to Buy InvestorPlace
Feb-23-19 08:10PM  Better Buy: bluebird bio vs. Gilead Sciences Motley Fool
Feb-22-19 08:00AM  The Top 5 Biotech Stocks Are Facing Growth Challenges Are Any Immune? Investor's Business Daily
Feb-21-19 09:39PM  What Pharma Investors Need to Know About Pfizer's Latest Disaster Motley Fool
09:47AM  2 Frustrating Flops, Plus Welcome to the Wrinkle Wars Motley Fool
09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
08:11AM  Intercept Reports Positive Top-Line Data for NASH, Shares Up Zacks
Feb-19-19 04:30PM  After Gilead Failed, Intercept Stock Rises On NASH Treatment Study Investor's Business Daily
10:58AM  Intercept Comes in First With Liver Drug, But Race Isnt Over Bloomberg
10:36AM  Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial Benzinga
08:00AM  Gilead Receives Approval in Canada for YESCARTA (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy CNW Group
Feb-17-19 09:00AM  Better Buy: Celgene vs. Gilead Sciences Motley Fool
Feb-15-19 04:40PM  U.S. Medicare plans to track CAR-T cancer therapy outcomes Reuters
04:09PM  Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. Moody's
02:16PM  Medicare would cover CAR-T therapies under new CMS proposal MarketWatch
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
10:08AM  Should You Buy Viking Therapeutics After Gilead Drug Failure? InvestorPlace
Feb-13-19 04:22PM  Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure Benzinga
03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
11:40AM  Celgene vs. Gilead Stock: Whats the Better Biotech Buy? InvestorPlace
Feb-12-19 05:50PM  Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target American City Business Journals
04:24PM  Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib TheStreet.com
04:20PM  Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails Zacks
04:15PM  Gilead Flops In Liver Disease Does Its Second Shot Have A Chance? Investor's Business Daily
03:55PM  5 Must-See Stock Charts for Wednesday: GILD, NFLX, EA InvestorPlace
02:57PM  Here's Why Viking Therapeutics Rose as Much as 13.9% Today Motley Fool
01:05PM  Gilead Sciences Stock Slides Lower on NASH Drug Failure InvestorPlace
12:12PM  Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech Benzinga
12:06PM  Gilead Sciences Stock Tumbles After Being Hit With Disappointing Trial Data Barrons.com
11:01AM  Viking Therapeutics Breaks Out After Gilead's Clinical Failure Investopedia
09:21AM  Gilead's Liver-Drug Setback Clouds  $35 Billion Dream Bloomberg
09:07AM  Gilead's Failed NASH Drug Trial Drags Stock Lower Benzinga
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
07:17AM  Better Buy: Gilead Sciences vs. Pfizer Motley Fool
03:06AM  Stocks - EA Jumps in Premarket; Walmart, Amazon Rise; Gilead, Aurora Slump Investing.com
01:41AM  Stocks - U.S. Futures Jump as Congress Makes Border Wall Deal Investing.com
Feb-11-19 06:00PM  Gilead misses key goal in NASH liver disease trial, shares sink Reuters
05:45PM  Gilead Slips After Liver Disease Treatment Fails In Late-Stage Test Investor's Business Daily
04:48PM  Gilead stock down nearly 4% as drug trial fizzles MarketWatch
04:30PM  Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Business Wire
01:04PM  Stocks Moving After Hours: Bruker, Molina Health, Gilead, Activision Investing.com
Feb-10-19 07:32PM  [$$] Big Pharmas Big Cancer Hope Is Fizzling The Wall Street Journal
12:00PM  Why Gilead Sciences Stock Perked Up in January Motley Fool
Feb-08-19 10:25AM  Why Agenus Inc. Stock Took Flight in January Motley Fool
Feb-07-19 03:03PM  For Sale: Performance Stocks, Slightly Worn Benzinga
09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 01:40PM  4 New CEOs to Watch in 2019 Investopedia
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
06:15AM  How Should You Value Gilead Sciences, Inc.s (NASDAQ:GILD)? Simply Wall St.
Feb-05-19 11:04PM  Edited Transcript of GILD earnings conference call or presentation 4-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:30PM  7 Key Things You Need to Know From Gilead Sciences' Q4 Earnings Update Motley Fool
05:02PM  Stock Market Today: Alphabet Grows While Gilead Sciences Shrinks Motley Fool
04:23PM  Gilead Sciences Drops Following Earnings Miss TheStreet.com
03:49PM  5 Top Stock Trades for Wednesday: GOOGL, GILD, EL, BA InvestorPlace
03:26PM  Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4 Benzinga
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM